Holen Sie sich die Stockscreener-App
21.57
0.19%
0.04
Handel nachbörslich:
21.57
Schlusskurs vom Vortag:
$21.53
Offen:
$21.12
24-Stunden-Volumen:
202.27K
Relative Volume:
0.81
Marktkapitalisierung:
$323.58M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-64.47M
KGV:
-21.79
EPS:
-0.99
Netto-Cashflow:
$-52.33M
1W Leistung:
+4.71%
1M Leistung:
+2.81%
6M Leistung:
-1.33%
1J Leistung:
+290.05%
1-Tages-Spanne:
$21.00
$22.20
1-Wochen-Bereich:
$19.41
$23.11
52-Wochen-Spanne:
$5.00
$31.01
Jasper Therapeutics Inc Stock (JSPR) Company Profile
Firmenname
Jasper Therapeutics Inc
Sektor
Branche
Telefon
(650) 549-1400
Adresse
2200 BRIDGE PKWY SUITE #102, REDWOOD CITY
Vergleichen Sie JSPR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
JSPR
Jasper Therapeutics Inc
|
21.57 | 323.58M | 0 | -64.47M | -52.33M | -6.1852 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Jasper Therapeutics Inc Stock (JSPR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-06 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-09-09 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-07-08 | Eingeleitet | BTIG Research | Buy |
| 2024-06-27 | Eingeleitet | Stifel | Buy |
| 2024-05-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-04-03 | Eingeleitet | Evercore ISI | Outperform |
| 2024-03-28 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-03-18 | Eingeleitet | TD Cowen | Outperform |
| 2023-08-11 | Eingeleitet | CapitalOne | Overweight |
| 2022-02-28 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-11-08 | Eingeleitet | Credit Suisse | Outperform |
| 2021-10-21 | Eingeleitet | William Blair | Outperform |
| 2021-10-20 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-10-13 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Jasper Therapeutics Inc Aktie (JSPR) Neueste Nachrichten
Wellington Management Group LLP Buys New Position in Jasper Therapeutics, Inc. (NASDAQ:JSPR) - MarketBeat
(JSPR) Trading Signals - Stock Traders Daily
Fmr LLC Makes New $722,000 Investment in Jasper Therapeutics, Inc. (NASDAQ:JSPR) - MarketBeat
Jasper Therapeutics' SWOT analysis: briquilimab's promise lifts stock outlook - Investing.com India
Jasper Therapeutics' SWOT analysis: briquilimab's promise lifts stock outlook By Investing.com - Investing.com South Africa
Head to Head Contrast: Jasper Therapeutics (NASDAQ:JSPR) versus Immunovant (NASDAQ:IMVT) - Defense World
Jasper Therapeutics COO Mahal Singh sells $19,899 in stock - Investing.com
Jasper Therapeutics COO Mahal Singh sells $19,899 in stock By Investing.com - Investing.com UK
Verition Fund Management LLC Invests $477,000 in Jasper Therapeutics, Inc. (NASDAQ:JSPR) - MarketBeat
Analysts Set Jasper Therapeutics, Inc. (NASDAQ:JSPR) Target Price at $73.38 - Defense World
When (JSPR) Moves Investors should Listen - Stock Traders Daily
BMO Capital Markets Initiates Coverage on Jasper Therapeutics (NASDAQ:JSPR) - Defense World
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Jasper Therapeutics (NASDAQ:JSPR) versus PharmaCyte Biotech (OTCMKTS:PMCBD) Head to Head Comparison - Defense World
BMO Capital Initiates Coverage of Jasper Therapeutics (JSPR) with Outperform Recommendation - MSN
BMO Capital Markets Begins Coverage on Jasper Therapeutics (NASDAQ:JSPR) - MarketBeat
Jasper Therapeutics shares rise on BMO's Outperform rating By Investing.com - Investing.com Canada
Samsara BioCapital LLC Boosts Stock Position in Jasper Therapeutics, Inc. (NASDAQ:JSPR) - MarketBeat
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Short Interest Up 10.2% in November - Defense World
Jasper Therapeutics, Inc. Doses First Patient in Phase 1b/2a ETESIAN Clinical Study of Briquilimab in Asthma - Marketscreener.com
Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a ETESIAN Clinical Study of Briquilimab in Asthma - GlobeNewswire
Jasper Therapeutics Launches Phase 1b/2a Asthma Trial, Expands Briquilimab Program | JSPR Stock News - StockTitan
Braidwell LP Invests $9.09 Million in Jasper Therapeutics, Inc. (NASDAQ:JSPR) - MarketBeat
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Shares Purchased by Ally Bridge Group NY LLC - MarketBeat
Learn to Evaluate (JSPR) using the Charts - Stock Traders Daily
Great Point Partners LLC Sells 79,635 Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) - MarketBeat
Addiction Therapeutics Market to Observe Strong Growth by 2030| Abbott, Denali Therapeutics - Newstrail
Jasper Therapeutics: Briquilimab's Potential In Chronic Urticaria And Asthma (NASDAQ:JSPR) - Seeking Alpha
We're Keeping An Eye On Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn Rate - Yahoo Finance
Is Jasper Therapeutics (JSPR) the Best Multibagger Stock to Buy Heading into 2025? - Yahoo Finance
10 Best Multibagger Stocks To Buy Heading into 2025 - Insider Monkey
Jasper Therapeutics' SWOT analysis: briquilimab's potential reshapes mast cell stock - Investing.com
Jasper Therapeutics to Participate at Upcoming Investor Conferences - GlobeNewswire
Jasper Therapeutics to Present Briquilimab Updates at Major Healthcare Conferences | JSPR Stock News - StockTitan
Analysts Set Jasper Therapeutics, Inc. (NASDAQ:JSPR) Price Target at $74.86 - MarketBeat
Stifel Initiates Coverage of Jasper Therapeutics (JSPR) with Buy Recommendation - MSN
Amplitude Healthcare Acquisition (OTCMKTS:AMHCU) News: Jasper Therapeutics, Inc. Reports Third Quarter 2024 Results - Defense World
Analysts Bullish on Jasper Therapeutics as Briquilimab Trials Show Promise - GuruFocus.com
Jasper Therapeutics Advances in Antibody Therapy Development - TipRanks
Jasper Therapeutics Inc (JSPR) Quarterly 10-Q Report - Quartzy
McDonald's Corp (MCD-N) QuotePress Release - The Globe and Mail
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
Jasper Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire
TSX Oil and Gas EW Index (TXOE) QuotePress Release - The Globe and Mail
Nasdaq Other Finance Index (OFIN) QuotePress Release - The Globe and Mail
(JSPR) Long Term Investment Analysis - Stock Traders Daily
Urticaria Clinical Trial Pipeline Accelerates: 20+ Leading Companies Pioneering New Treatments | DelveInsight - GlobeNewswire
Net Present Value Model: Jasper Therapeutics Inc’s Briquilimab - GlobalData
JSPRJasper Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Long Term Trading Analysis for (JSPR) - Stock Traders Daily
Jasper Therapeutics' SWOT analysis: briquilimab stock shows promise amid challenges - Investing.com
Finanzdaten der Jasper Therapeutics Inc-Aktie (JSPR)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):